S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D., Stambolija, V., Zoricic, Z., Vrcic, H., & Sebecic, B
not approved Tirzepatide (Zepbound) Approved (Zepbound, Mounjaro) Semaglutide alone (Wegovy) Approved (Wegovy, Ozempic) Cagrilintide alone Investigational Feature Head-to-head data CagriSema Did not meet non-inferiority vs tirzepatide at 84 wks (Reuters Feb 2026) Tirzepatide (Zepbound) Semaglutide alone (Wegovy) Cagrilintide alone These compounds are not interchangeable
Phase 2 monotherapy data reported up to 10.8% body weight reduction at the 4.5 mg dose versus 3.0% with placebo at week 26 [2]
They explain tirzepatide in isolation, or they mention B12 as a footnote
Heaters: Mats run in a very safe zone of 0.2-0.8 milligauss
Reported improvements included lower blood pressure, triglycerides, and waist circumference